

Prism Medico & Pharmacy Limited

CIN: L51109PB2002PLC047444

D-118, INDUSTRIAL AREA,
PHASE VII, MOHALI-160055

Telephone no – 0172-5020762

Email Id →investorgrievancewmcl@gmail.com

Date: 14/02/2019


To, Department of Corporate Services, BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001.	To, Listing Department, Metropolitan Stock Exchange of India Ltd. (MSE) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098, India. ISIN : INE730E01016 SYMBOL: PRISMEDI
Scip Code: 512217	

Subject: Outcome of Board Meeting held on Thursday, 14th February, 2019

Dear Sir/Madam

Pursuant to the provisions of Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors in their meeting held on **Thursday, 14th February, 2019 at 4.00 p.m. and concluded at 4:30 p.m. :**

1. Considered and Approved and taken on records the Unaudited Financial results along with the Limited Review Report for the quarter ended on 31st December, 2018 (standalone and consolidated) as recommended by the Audit Committee.
Further, we hereby enclose the following



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report on Consolidated Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Consolidated Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 31st Dec 2018 ("the Statement") and its subsidiary naming M/s Healthy Biosciences Private Limited attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The Consolidated Statement includes the financial results of the following entity naming M/s Healthy Biosciences Private Limited.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Consolidated Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 14-02-2019
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N


CA Suprit Kaur
Partner
M.No 424986



PRISM MEDICO AND PHARMACY LTD.
CIN : L51109PB2002PLC047444.

Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):

(1)BASIC	0.24	0.46	-0.19	-0.01
(2)DILUTED	0.24	0.46	-0.19	-0.01

Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):

(1)BASIC	0.24	0.46	-0.19	-0.01
(2)DILUTED	0.24	0.46	-0.19	-0.01

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH February, 2019.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

Place : Mohali

Date : 14.02.2019

**FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.**

Gursimran Singh
Gursimran Singh Director


DIN: 02209675

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON 31ST DECEMBER, 2018

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	31.12.2018	31.03.2018
I. EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	606.34	606.34
(B) RESERVES AND SURPLUS	746.50	600.04



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report

Review Report To The Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the accompanying statement of Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 31st Dec 2018 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-Audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14-February-2019
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N

CA Suprit Kaur
Partner
M.No 424986



PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)			Year Ended (Audited)
	31.12.2018	30.09.2018	31.12.2017	31.03.2018

17	Paid-up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	718.81	718.81	673.69	673.69
19	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):				
	(1)BASIC	0.48	0.42	0.07	-0.03
	(2)DILUTED	0.48	0.42	0.07	-0.03
	Earnings Per Share (after extraordinary items) (of Rs ___/- each)				

not annualised.

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 31ST DECEMBER, 2018

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	31.12.2018	31.03.2018
I. EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	606.34	606.34
(B) RESERVES AND SURPLUS	747.75	671.80
(C) MONEY RECEIVED AGAINST SHARE WARRANTS	0.00	0.00
SUB-TOTAL - SHAREHOLDERS' FUNDS	1354.09	1278.14
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT	0.00	0.00
(3) MINORITY INTEREST *	0.00	0.00
(4) NON CURRENT LIABILITIES	0.00	0.00